Close Menu

Lung Cancer

News and reporting on lung cancer.

In a study, Merck scientists identified 71 phosphoproteins that could be useful biomarkers for predicting the efficacy of drugs targeting a cancer-linked signaling pathway.

The company next year plans to launch a 1,000-patient verification trial for its lung cancer protein biomarker panel, with trials for its Alzheimer's disease panel likely to follow, said an official.

The center will focus on developing biomarker panels for measuring patient response to drug treatments for lung cancer, chronic obstructive pulmonary disease, and cardiovascular disease, said one of its founders.

The company will be using the funds to develop and test a prototype of the diagnostic, which it hopes to bring to market sometime in 2011, said a company official.

Roche presents data from HPV Dx trial; Epigenomics launches Epi proLung BL Reflex Assay in Europe.

A company official said that VeriStrat sales are growing at a double-digit pace and that Biodesix is also looking to apply the test to diseases beyond lung cancer.

Epigenomics' PCR-based lung cancer reflex diagnostic test has been validated in a key clinical trial, clearing the way for the test to receive the CE Mark for in vitro diagnostics and for the company to launch the test in Europe in coming weeks.

Proteomics research papers of note, June 2010

The company said that the placing was intended to raise money for capital investment in equipment for its PS Biomarker Services division and to finance the further development of tandem mass tag-SRM mass spectrometry assays for its proprietary biomarkers.

The firm claims the test can detect cancers as much as five years earlier than current testing methods.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.